Prostate Cancer - Results from #1680

Comparison of Multiple Segmentation Methods for Volumetric Delineation of Primary Prostate Cancer with Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL PET/CT. December 7, 2023

Association of PSMA PET-derived Parameters and Outcomes of Patients Treated for Oligorecurrent Prostate Cancer. December 7, 2023

Patient and physician perspectives on treatments for low-risk prostate cancer: a qualitative study. December 7, 2023

Activation of Dendritic Cells Isolated from the Blood of Patients with Prostate Cancer by Ex Vivo Fluid Shear Stress Stimulation. December 6, 2023

Long-Term Impact of Medicaid Expansion on Prostate Cancer Screening. December 6, 2023

Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study. December 6, 2023

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. December 6, 2023

Positive Surgical Margins After Anterior Robot-assisted Radical Prostatectomy: Assessing the Learning Curve in a Multi-institutional Collaboration. December 6, 2023

Adipose triglyceride lipase is a therapeutic target in advanced prostate cancer that promotes metabolic plasticity. December 5, 2023

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. December 5, 2023

Recurrent prostate cancer: combined role for MRI and PSMA-PET in 68Ga-PSMA-11 PET/MRI. December 5, 2023

Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study. December 5, 2023

Elective Nodal Irradiation for Oligorecurrent Nodal Prostate Cancer: Interobserver Variability in the PEACE V-STORM Randomized Phase 2 Trial. December 5, 2023

Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI's "big data for better outcomes" program. December 5, 2023

Phenotype plasticity and altered sensitivity to chemotherapeutic agents in aggressive prostate cancer cells. December 5, 2023

Racial and Ethnic Disparities in Use of Novel Hormonal Therapy Agents in Patients With Prostate Cancer. December 4, 2023

Novel hormone therapy and coordination of care in high-risk biochemically recurrent prostate cancer. December 4, 2023

Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men. December 4, 2023

Prediction models of incontinence and sexual function one year after radical prostatectomy based on data from 20 164 prostate cancer patients. December 4, 2023

Comparison of Urinary Diversion in Patients with Prostatic Fistula to Those with Localized Radiation Injury after Radiotherapy for the Treatment of Prostate Cancer. December 4, 2023

Page 85 of 1435